Early morning trading on the big boards is mixed after a trio of bad economic reports came out. Initial claims missed, PPI was decidedly ugly and retail sales were off. Commodity prices continued to slump, but gas stations evidently didn’t receive the memo as the average price rose 2 cents overnight. Internationally the EU continues to deal with the debt issues of the peripheral countries – namely Portugal and Greece. The IMF issued a warning that the core Eurozone countries remain exposed to the debt contagion posed by the peripheral countries. Amid all of this uncertainty several stocks have been on the rise this morning.
DynaVox Inc. (NASDAQ:DVOX) shares rose sharply this morning climbing $1.92 to $7.97 per share. DVOX is up on huge volume with over 700 thousand shares traded in midday trading. DynaVox reported net sales of $28.7 million in its 3Q, a 1% rise from the same period last year. The company which specializes in communication products for individuals with significant speech, language, and learning disabilities saw sales of its speech generating devices rise 1.3%.
Discovery Laboratories, Inc (NASDAQ:DSCO) shares are on the rise this morning up 25% at $2.71 per share. Nearly 5.3 million shares have been traded this morning, well above its average daily volume of 400 thousand shares. in Discovery Laboratories stock. The increase comes as the company reported its 1Q results and updated some of its selected pipeline developments. One such developments is the Aerosolization Technology in which a collaborative study indicated that the Aerosolized KL4 surfacant significantly improved Lung function and survival in the treatment of Acute Lung Injuries. Discovery Laboratories hopes to seek regulatory guidance from the US and Europe this year.
Oxigene Inc. (NASDAQ:OXGN) shares have climbed this morning rising 16% to $5.71 per share. The rise in Oxigene stock comes in conjunction with the announced initiation of Phase 1 trial of OXi4503. OXi4503 is a next generation anticancer agent that will be administered in patients with acute Myelogenous Leukemia and Myelodysplastic syndrome. The Leukemia and Lymphoma and Society will provide study support.